Australia is anticipating the arrival of Retatrutide, a novel medication developed by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, demonstrates significant efficacy in clinical trials, https://johsocial.com/story12693293/retatrutide-australia-a-new-solution-for-losing-weight